Choongwe's new bio drug for stroke using stem cells on phase III study.

Published: 2005-07-05 06:58:00

Updated: 2005-07-05 06:58:00

Choongwe exchanged a memorandum of understanding with FCB Pharmaicell FCBP) on June 30 jointly to develope a new drug for the treatment of stroke using stem cells, for which FCBP obtained an IND from the KFDA for its phase III clinical study. The Memorandum describes a joint development plan betw...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK